⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL80655 | 1.00 | — | — | |
| SCHEMBL1806242 | 1.00 | — | — | |
| SCHEMBL1980598 | 0.83 | GABRP (0.31) | — | |
| SCHEMBL19136540 | 0.83 | GABRP (0.31) | — | |
| SCHEMBL2551857 | 0.83 | GABRP (0.31) | — | |
| SCHEMBL28608405 | 0.82 | CA2 (0.31) | — | |
| SCHEMBL68248 | 0.80 | CACNA2D1 (0.32) | — | |
| SCHEMBL18341048 | 0.80 | ENPEP (0.32) | — | |
| SCHEMBL399158 | 0.80 | HMGCR (0.31) | — | |
| SCHEMBL18341050 | 0.80 | ENPEP (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4371982-A2 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | RQX Pharmaceuticals, Inc. (US) | 2024-05-22 | — | — | EP | disclosed |
| EP-3583096-B1 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | RQX PHARMACEUTICALS INC (US) | 2024-03-27 | — | — | EP | disclosed |
| WO-2023185073-A1 | PARP7 INHIBITOR AND USE THEREOF | 诺沃斯达药业(上海)有限公司 | 2023-10-05 | — | — | WO | disclosed |
| US-20230133667-A1 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | RQX PHARMACEUTICALS INC (US) | 2023-05-04 | — | — | US | disclosed |
| US-20210198316-A9 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | CHARLES RIVER DISCOVERY RESEARCH SERVICES UK LIMITED (GB) | 2021-07-01 | — | — | US | disclosed |
| CN-110590668-A | Preparation method of N- [ (1S) -2- [3- (3-chloro-4-cyanophenyl) -1H-pyrazol-1-yl ] -1-methylethyl ] -5- (1-hydroxyethyl) -1H-pyrazole-3-formamide | 江苏君若医药有限公司 | 2019-12-20 | — | — | CN | disclosed |
| US-9505761-B2 | Bicyclic compounds and their use as antibacterial agents and beta-lactamase inhibitors | FEDORA PHARMACEUTICALS INC. (CA) | 2016-11-29 | — | — | US | disclosed |
| US-9365506-B2 | Compounds and compositions as TLR2 agonists | NOVARTIS AG (CH) | 2016-06-14 | — | — | US | disclosed |
| US-9067934-B2 | Bicyclic pyridinones | PFIZER INC. (US) | 2015-06-30 | — | — | US | disclosed |
| EP-2699561-B1 | ANDROGEN RECEPTOR MODULATING CARBOXAMIDES | ORION CORP (FI) | 2015-06-03 | — | — | EP | disclosed |
| US-20140288051-A1 | BICYCLIC COMPOUNDS AND THEIR USE AS ANTIBACTERIAL AGENTS AND BETA-LACTAMASE INHIBITORS | FEDORA PHARMACEUTICALS INC. (CA) | 2014-09-25 | — | — | US | disclosed |
| US-8796257-B2 | Bicyclic compounds and their use as antibacterial agents and β-lactamase inhibitors | NAEJA PHARMACEUTICAL INC. (CA) | 2014-08-05 | — | — | US | disclosed |
| EP-2727918-A1 | Compounds and Compositions as Protein Kinase Inhibitors | IRM LLC (BM) | 2014-05-07 | — | — | EP | disclosed |
| US-8697673-B2 | Bicyclic pyridinones | PFIZER INC. (US) | 2014-04-15 | — | — | US | disclosed |
| US-20130225554-A1 | NEW BICYCLIC COMPOUNDS AND THEIR USE AS ANTIBACTERIAL AGENTS AND BETA-LACTAMASE INHIBITORS | NAEJA PHARMACEUTICAL INC. (CA) | 2013-08-29 | — | — | US | disclosed |
| US-20120252758-A1 | Novel Bicyclic Pyridinones | PFIZER INC. | 2012-10-04 | — | — | US | disclosed |
| US-8071568-B2 | Nucleoside aryl phosphoramidates for the treatment of RNA-dependent RNA viral infection | MERCK SHARP & DOHME CORP. (US) | 2011-12-06 | — | — | US | disclosed |
| US-20110263562-A1 | BICYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-10-27 | — | — | US | disclosed |
| WO-2011051540-A1 | ANDROGEN RECEPTOR MODULATING COMPOUNDS | ORION CORPORATION (FI) | 2011-05-05 | — | — | WO | disclosed |
| US-20080318947-A1 | Inhibitors of Akt Activity | HEERDING DIRK A | 2008-12-25 | — | — | US | disclosed |